Policy News

ISSCR Comments on New Biomedical Technology Regulations in China

  • 29 March, 2019
In response to draft regulations in China on gene editing and other potentially risky biomedical technologies, the ISSCR has submitted comments to the the country's National Health Commission Medical and Medical Administration Bureau

Under the proposed measures, technology invoiving gene editing, gene transfer, and gene regulation would be categorized as "high-risk," and managed by the health department of the State Council, China's Cabinet. The ISSCR comments address ensuring compliance with ethical research standards, standards of informed consent, and international standards for human embryo genome modification, among others.